Gilead Sciences, Inc. $GILD Shares Sold by Dodge & Cox

Key Points

• Dodge & Cox reduced its holdings in Gilead Sciences by 0.8%, selling 252,926 shares and retaining 32,694,791 shares, which represents about 2.1% of its portfolio.
• Gilead reported a quarterly earnings per share (EPS) of $2.01, surpassing estimates by $0.05, with revenues reaching $7.08 billion.
• The company announced a quarterly dividend of $0.79 per share, leading to an annualized dividend yield of 2.8%, which will be paid on September 29th.

Dodge & Cox trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 0.8% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 32,694,791 shares of the biopharmaceutical company's stock after selling 252,926 shares during the period. Gilead Sciences comprises 2.1% of Dodge & Cox's holdings, making the stock its 11th biggest holding. Dodge & Cox owned approximately 2.63% of Gilead Sciences worth $3,663,451,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the company. Redwood Financial Network Corp grew its holdings in Gilead Sciences by 4.0% during the 4th quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company's stock valued at $234,000 after purchasing an additional 98 shares during the last quarter. Argentarii LLC boosted its position in Gilead Sciences by 3.0% in the 1st quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company's stock valued at $380,000 after buying an additional 99 shares during the period. Peak Financial Advisors LLC boosted its position in Gilead Sciences by 1.7% in the 1st quarter. Peak Financial Advisors LLC now owns 6,040 shares of the biopharmaceutical company's stock valued at $677,000 after buying an additional 100 shares during the period. Perkins Coie Trust Co boosted its position in Gilead Sciences by 2.6% in the 1st quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company's stock valued at $435,000 after buying an additional 100 shares during the period. Finally, Investment Research & Advisory Group Inc. boosted its position in Gilead Sciences by 33.3% in the 1st quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock valued at $45,000 after buying an additional 100 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on GILD shares. UBS Group boosted their price objective on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a research report on Friday, August 8th. Daiwa Capital Markets raised shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price objective for the company in a research report on Tuesday, August 19th. Royal Bank Of Canada boosted their price objective on shares of Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a research report on Friday, August 8th. Daiwa America raised shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. Finally, Truist Financial raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and upped their price target for the stock from $108.00 to $127.00 in a research report on Friday, August 8th. Three research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $115.39.

Gilead Sciences Stock Down 0.5%

NASDAQ:GILD traded down $0.62 during midday trading on Monday, reaching $114.15. 3,812,165 shares of the stock traded hands, compared to its average volume of 6,667,523. Gilead Sciences, Inc. has a 12-month low of $76.42 and a 12-month high of $121.83. The business has a 50-day moving average of $112.57 and a two-hundred day moving average of $109.28. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The stock has a market capitalization of $141.64 billion, a PE ratio of 22.74, a price-to-earnings-growth ratio of 0.70 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. The company had revenue of $7.08 billion during the quarter, compared to analysts' expectations of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. Gilead Sciences's revenue for the quarter was up 1.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Monday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is 62.95%.

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $296,325.00. Following the completion of the transaction, the chief financial officer owned 160,110 shares of the company's stock, valued at $18,977,838.30. This trade represents a 1.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction on Monday, July 28th. The shares were sold at an average price of $113.94, for a total transaction of $1,139,400.00. Following the sale, the chief executive officer owned 605,725 shares in the company, valued at approximately $69,016,306.50. This represents a 1.62% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 82,000 shares of company stock worth $9,339,230. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.